News

A Phase 2 clinical trial of AB-1005, AskBio’s gene therapy for Parkinson’s disease, has randomly assigned its first participants to different treatment groups, the company has announced. Called REGENERATE-PD (NCT06285643), the trial is expected to enroll about 87 adults with moderate Parkinson’s, ages 45 to 75, who…

Aspen Neuroscience has completed dosing the first two groups of patients in ASPIRO, an ongoing Phase 1/2a clinical trial that’s testing the safety and tolerability of ANPD001, an investigational cell therapy for Parkinson’s disease. Patients with moderate to severe Parkinson’s who have so far received ANPD001, which uses…

BlueRock Therapeutics said it is progressing its investigational cell therapy, bemdaneprocel, into a Phase 3 clinical trial set to begin in the first half of 2025. The trial, named exPDite-2, will assess the safety and efficacy of the treatment for moderate Parkinson’s disease. This decision comes after positive…

Medtronic’s BrainSense adaptive deep brain stimulation (aDBS) system and electrode identifier have received CE Mark approval in the European Union (EU) and the U.K. for the management of Parkinson’s disease. CE Mark approval indicates that the European Commission, the EU’s regulatory body, considered Medtronic’s system to meet…

Levodopa, a standard Parkinson’s disease medication, may help alleviate muscle stiffness, one of the condition’s characteristic motor symptoms, by slowing the speed of electrical signals sent to muscles during movement, particularly when muscles are required to stretch quickly, a small study reports. Using a robotic device to help measure…

The number of copies of mitochondrial DNA in the blood of people with Parkinson’s disease are not a biomarker of poorly functioning mitochondria — the source of energy that powers cells — but may instead reflect immune responses that occur outside the brain, a study found. The findings, which…

Gain Therapeutics has set up a clinical advisory board made up of leading Parkinson’s experts in genetics, biomarkers, and trial design to guide the advancement of GT-02287, its investigational therapy for Parkinson’s disease. The advisory board will collaborate with Gain’s leadership to guide GT-02287 through its potential Phase…

A research project that’s designed to help improve communication for people with Parkinson’s disease by focusing on listener training has been awarded a $2.6 million, five-year grant from the National Institutes of Health (NIH). The funding will help researchers implement a structured listener training program and test its effectiveness in…

The first patient in a Phase 2 clinical study testing BIA 28-6156 — a small molecule in the pipeline at Bial for treating Parkinson’s disease in people with mutations in the GBA1 gene — has completed the full dose regimen, the company announced. The goal of the study,…

Mytos and Aspen Neuroscience are teaming up to automate the manufacture of autologous dopaminergic neuronal precursor cells (DNPCs) for ANPD001, Aspen’s experimental cell therapy program for Parkinson’s disease. As part of the agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing…